Shots:
- The EC has approved Zenrelia (ilunocitinib) for the treatment of pruritus linked to allergic dermatitis & clinical symptoms of atopic dermatitis in dogs (≥12mos.)
- As part of the EU approval process, Elanco conducted an H2H non-inferiority study in 338 dogs across 25 sites in 4 countries, which showed that Zenrelia (QD) is at least as effective as oclacitinib at the 1EP on Day 28; data were published in Veterinary Dermatology
- Additionally, Elanco expects to launch Zenrelia in the EU by the end of Q3’25 & additional approvals in other regions across the globe
Ref: PRNewswire | Image: Elanco | Press Release
Related News:- Neurizon Therapeutics Licenses Monepantel from Elanco Animal Health to Accelerate NUZ-001 Commercialization
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
